Fylom
Back to What comes next
The end of aging: how close the science really is, and what breaks if it works

What comes next

The end of aging: how close the science really is, and what breaks if it works

12 min

Sort the real longevity science from the wishful thinking, then ask the harder question — if we genuinely slow aging, what happens to careers, pensions, inequality, and society itself.

Listen on the app, request early access:

Show notes

Twelve biological hallmarks like senescent cells drive decay and act like bad apples in a barrel.

Metformin and rapamycin show promise for extending healthspan by targeting the cellular general contractor protein.

Epigenetic reprogramming can restore youthful gene expression in mice without deleting the cell's operating system.

The current three-stage life model fails when retirement lasts fifty years instead of fifteen.

Scientific progress risks stalling because new ideas often advance only when older leaders pass away.

Compressed morbidity aims for people to live vibrantly until one hundred then go out like a light.

In this episode

  1. 1Intro1 min
  2. 2The Biological Hallmarks and the Hype Gap3 min
  3. 3The Pharmacological Frontier: Metformin to Yamanaka Factors3 min
  4. 4The Economic Fracture: Pensions and the Multi-Stage Life3 min
  5. 5The Social Cost of Success2 min
  6. 6Outro1 min

Sources

Fylom generates episodes like this on any topic you're curious about.

Fylom episodes are researched and written by AI. Automated checks help catch inaccuracies, but episodes aren't reviewed by a human and AI can still get things wrong. Treat them as a starting point, not a source of record — more in our accuracy disclaimer.

The end of aging: how close the science really is, and what breaks if it works — Fylom